Studies showed that vascular disrupting agents and angiogenesis inhibitors had a synergistic effect for the treatment of cancer. Few previous reports used MRI to assess the combination of anti-angiogenesis drugs in non-small cell lung cancer(NSCLC). MR multi-b value diffusion-weighted imaging can be used to monitor the treatment of tumor by anti-angiogenesis drugs. In our study , the nude mice xenograft model was used to evaluate the role of vascular disrupting agents combing angiogenesis inhibitor in NSCLC by multiple b-value diffusion weighted imaging (DWI).
This abstract and the presentation materials are available to members only;
a login is required.
